Castle Biosciences Swings to Loss Amid Soaring Amortization Costs

Ticker: CSTL · Form: 10-Q · Filed: 2025-11-03T00:00:00.000Z

Sentiment: bearish

Topics: Diagnostics, Biotechnology, Net Loss, Amortization Expense, Cash Flow, Acquisitions, Operating Expenses

Related Tickers: CSTL

TL;DR

**CSTL's Q3 loss and massive amortization jump mean their acquisition strategy is bleeding cash, making it a risky bet right now.**

AI Summary

CASTLE BIOSCIENCES INC reported a net loss of $501 thousand for the three months ended September 30, 2025, a significant decline from a net income of $2.269 million in the same period of 2024. For the nine months ended September 30, 2025, the company posted a net loss of $21.826 million, compared to a net income of $8.655 million in the prior year. Total net revenues decreased to $83.043 million for the three months ended September 30, 2025, from $85.782 million in 2024, but increased to $257.219 million for the nine months ended September 30, 2025, up from $245.758 million. Operating expenses surged to $89.847 million for the three months and $296.202 million for the nine months, primarily driven by a substantial increase in amortization of acquired intangible assets to $32.562 million for the nine months ended September 30, 2025, from $6.766 million in 2024. The company's cash and cash equivalents decreased to $85.556 million as of September 30, 2025, from $119.709 million at December 31, 2024, while marketable investment securities increased to $201.986 million. An asset acquisition of $18.726 million and purchases of property and equipment totaling $28.837 million contributed to a net cash outflow from investing activities of $69.198 million for the nine months.

Why It Matters

This shift from profit to loss, particularly the $21.826 million net loss for the nine months, signals a challenging period for CASTLE BIOSCIENCES INC and could impact investor confidence. The substantial increase in amortization of acquired intangible assets, jumping from $6.766 million to $32.562 million, suggests recent acquisitions are heavily impacting profitability, potentially raising questions about the long-term value and integration of these assets. For employees, sustained losses could lead to cost-cutting measures, while customers might see impacts on product development or service expansion. In the competitive diagnostics market, this financial performance could weaken the company's position against rivals with stronger balance sheets and profitability.

Risk Assessment

Risk Level: high — The company reported a net loss of $21.826 million for the nine months ended September 30, 2025, a significant deterioration from a net income of $8.655 million in the prior year. This is compounded by a substantial increase in amortization of acquired intangible assets to $32.562 million, indicating significant ongoing costs from past acquisitions that are eroding profitability.

Analyst Insight

Investors should exercise caution and thoroughly evaluate the long-term profitability and integration strategy of CASTLE BIOSCIENCES INC's acquisitions. Monitor future filings for signs of improved revenue growth, cost control, and a reduction in the impact of amortization expenses on net income before considering an investment.

Financial Highlights

debt To Equity
0.02
revenue
$257.219M
operating Margin
-15.16%
total Assets
$562.786M
total Debt
$10.049M
net Income
-$21.826M
eps
N/A
gross Margin
N/A
cash Position
$85.556M
revenue Growth
4.7%

Revenue Breakdown

SegmentRevenueGrowth
Total Net Revenues$83.043M-3.2%
Total Net Revenues$257.219M+4.7%

Key Numbers

Key Players & Entities

FAQ

Why did Castle Biosciences report a net loss for the nine months ended September 30, 2025?

Castle Biosciences reported a net loss of $21.826 million for the nine months ended September 30, 2025, primarily due to a significant increase in total operating expenses to $296.202 million, up from $241.138 million in the prior year. A major contributor was the amortization of acquired intangible assets, which surged to $32.562 million from $6.766 million.

How did Castle Biosciences' revenue perform in Q3 2025?

For the three months ended September 30, 2025, Castle Biosciences' net revenues decreased to $83.043 million, compared to $85.782 million in the same period of 2024. However, for the nine months ended September 30, 2025, net revenues increased to $257.219 million from $245.758 million in 2024.

What was the impact of acquisitions on Castle Biosciences' financials?

Acquisitions had a notable impact, with amortization of acquired intangible assets increasing substantially to $32.562 million for the nine months ended September 30, 2025, from $6.766 million in the prior year. Additionally, the company incurred an asset acquisition, net of cash and cash equivalents acquired, of $18.726 million during the nine months ended September 30, 2025.

What is Castle Biosciences' current cash position?

As of September 30, 2025, Castle Biosciences had cash and cash equivalents of $85.556 million. This represents a decrease from $119.709 million reported at December 31, 2024.

What are the key risks highlighted in Castle Biosciences' 10-Q?

The 10-Q indicates a history of recurring net losses and negative cash flows, with an accumulated deficit of $222.0 million as of September 30, 2025. The significant increase in operating expenses, particularly amortization, and the net loss for the period are key financial risks.

How did operating expenses change for Castle Biosciences?

Total operating expenses for Castle Biosciences increased to $89.847 million for the three months ended September 30, 2025, from $80.703 million in 2024. For the nine months, operating expenses rose to $296.202 million from $241.138 million, largely driven by higher amortization of acquired intangible assets.

What is Castle Biosciences' outlook on meeting its cash requirements?

Castle Biosciences believes its $85.6 million of cash and cash equivalents and $202.0 million of marketable investment securities as of September 30, 2025, along with anticipated revenue, will be sufficient to meet cash requirements through at least the 12-month period following the issuance date of the financial statements.

What is the accumulated deficit for Castle Biosciences as of September 30, 2025?

As of September 30, 2025, Castle Biosciences had an accumulated deficit of $221.952 million. This is an increase from an accumulated deficit of $200.126 million as of December 31, 2024.

How much did Castle Biosciences spend on property and equipment?

For the nine months ended September 30, 2025, Castle Biosciences spent $28.837 million on purchases of property and equipment. This is an increase compared to $20.759 million spent in the same period of 2024.

What is Castle Biosciences' business focus?

Castle Biosciences, Inc. is a commercial-stage diagnostics company focused on providing clinicians and their patients with personalized, clinically actionable information to inform treatment decisions and improve health outcomes. Their laboratory operations are conducted in Phoenix, Arizona, and Pittsburgh, Pennsylvania.

Risk Factors

Industry Context

Castle Biosciences operates in the diagnostics and medical technology sector, focusing on solutions for skin conditions. The industry is characterized by rapid innovation, regulatory oversight, and competition from both established players and emerging companies. Reimbursement policies and physician adoption are critical success factors.

Regulatory Implications

As a healthcare company, Castle Biosciences is subject to stringent regulations from bodies like the FDA and CMS. Changes in reimbursement rates, new regulatory requirements for diagnostic tests, or compliance issues could significantly impact revenue and operations.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]

Key Dates

Glossary

Amortization of acquired intangible assets
The systematic allocation of the cost of an intangible asset over its useful life. For Castle Biosciences, this relates to assets acquired through business combinations. (A significant driver of increased operating expenses and net loss in the current period, rising from $6.766 million to $32.562 million for the nine months ended September 30, 2025.)
Accumulated deficit
The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Increased to $221.952 million as of September 30, 2025, indicating ongoing profitability challenges.)
Marketable investment securities
Securities that are readily convertible to cash and are held by the company for investment purposes. (Increased to $201.986 million as of September 30, 2025, suggesting a strategic shift or growth in the company's investment portfolio.)
Contingent consideration
An obligation to transfer additional consideration (usually cash or stock) to an seller in a business combination, contingent upon the occurrence of certain future events. (Appeared as a liability ($1.000 million current and $1.500 million noncurrent) as of September 30, 2025, suggesting recent acquisitions with potential future payments.)

Year-Over-Year Comparison

Compared to the prior year, Castle Biosciences has experienced a significant downturn in profitability, shifting from a net income of $8.655 million for the nine months ended September 30, 2024, to a net loss of $21.826 million for the same period in 2025. This is largely due to a substantial increase in operating expenses, most notably amortization of acquired intangible assets, which rose from $6.766 million to $32.562 million. While total net revenues saw a modest increase of 4.7% to $257.219 million for the nine-month period, the surge in expenses has overshadowed this growth, leading to a wider operating loss and a growing accumulated deficit.

Filing Stats: 4,634 words · 19 min read · ~15 pages · Grade level 16.4 · Accepted 2025-11-03 16:16:26

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1

Financial Statements

Item 1. Financial Statements 1 Condensed Consolidated Balance Sheets as of Se ptember 30, 2025 (Unaudited) and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Comprehensive (Loss) Income for the Three and Nine Months Ended September 30, 2025 and 2024 3 Unaudited Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 4 Unaudited Condensed Consolidated Statements of Cash Flows for the N ine Months Ended Sept ember 30, 2025 and 2024 6 Notes to Unaudited Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 27

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 45

Controls and Procedures

Item 4. Controls and Procedures 46

OTHER INFORMATION

PART II. OTHER INFORMATION 47

Legal Proceedings

Item 1. Legal Proceedings 47

Risk Factors

Item 1A. Risk Factors 47

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 55

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 55

Other Information

Item 5. Other Information 55

Exhibits

Item 6. Exhibits 56

SIGNATURES

SIGNATURES 57 i Table of Contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CASTLE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) September 30, 2025 December 31, 2024 ASSETS (unaudited) Current Assets Cash and cash equivalents $ 85,556 $ 119,709 Marketable investment securities 201,986 173,421 Accounts receivable, net 49,482 51,218 Inventory 8,650 8,135 Prepaid expenses and other current assets 11,895 7,671 Total current assets 357,569 360,154 Long-term accounts receivable, net 2,050 918 Property and equipment, net 84,885 51,122 Operating lease assets 15,151 11,584 Goodwill and other intangible assets, net 101,849 106,229 Other assets – long-term 1,282 1,228 Total assets $ 562,786 $ 531,235 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable $ 12,211 $ 6,901 Accrued compensation 31,763 32,555 Contingent consideration 1,000 — Operating lease liabilities 1,449 1,665 Current portion of long-term debt — 278 Other accrued and current liabilities 8,885 7,993 Total current liabilities 55,308 49,392 Long-term debt 10,049 9,745 Noncurrent portion of contingent consideration 1,500 — Noncurrent operating lease liabilities 25,302 14,345 Noncurrent finance lease liabilities 339 311 Deferred tax liability 3,242 1,607 Total liabilities 95,740 75,400 Commitments and Contingencies (Note 12) Stockholders' Equity Preferred stock, $ 0.001 par value per share; 10,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value per share; 200,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 29,161,863 and 28,483,195 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 29 28 Additional paid-in capital 688,729 655,703 Accumulated deficit ( 221,952 ) ( 200,126 ) Accumulated other comprehensive income 240 230 Total stockholders'

View on Read The Filing